Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

Basit Öğe Kaydı
dc.authorscopusid56201755200
dc.authorscopusid7004118459
dc.authorscopusid55683664900
dc.authorscopusid24173610000
dc.authorscopusid35377410100
dc.authorscopusid7003811242
dc.authorscopusid7102929864
dc.contributor.authorJaeger V.K.
dc.contributor.authorTikly M.
dc.contributor.authorXu D.
dc.contributor.authorSiegert E.
dc.contributor.authorHachulla E.
dc.contributor.authorAirò P.
dc.contributor.authorValentini G.
dc.date.accessioned2023-01-12T20:23:12Z
dc.date.available2023-01-12T20:23:12Z
dc.date.issued2020
dc.departmentN/A/Departmenten_US
dc.description.abstractRacial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. Methods: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. Results: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. Conclusion: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.en_US
dc.identifier.doi10.1093/rheumatology/kez486
dc.identifier.endpage1694en_US
dc.identifier.issn1462-0324
dc.identifier.issue7en_US
dc.identifier.pmid31680161en_US
dc.identifier.scopus2-s2.0-85088708108en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1684en_US
dc.identifier.urihttps://doi.org/10.1093/rheumatology/kez486
dc.identifier.urihttps://hdl.handle.net/11454/79660
dc.identifier.volume59en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofRheumatology (United Kingdom)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectorgan manifestationsen_US
dc.subjectracesen_US
dc.subjectsystemic sclerosisen_US
dc.subjectautoantibodyen_US
dc.subjectDNA topoisomeraseen_US
dc.subjectautoantibodyen_US
dc.subjectDNA topoisomeraseen_US
dc.subjectadulten_US
dc.subjectArticleen_US
dc.subjectAsianen_US
dc.subjectBlack personen_US
dc.subjectCaucasianen_US
dc.subjectcentromereen_US
dc.subjectclinical featureen_US
dc.subjectcohort analysisen_US
dc.subjectcontrolled studyen_US
dc.subjectdisease courseen_US
dc.subjectfemaleen_US
dc.subjectforced vital capacityen_US
dc.subjectgeographic distributionen_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectmortalityen_US
dc.subjectpriority journalen_US
dc.subjectpulmonary hypertensionen_US
dc.subjectrace differenceen_US
dc.subjectsystemic sclerosisen_US
dc.subjectageden_US
dc.subjectAsian continental ancestry groupen_US
dc.subjectBlack personen_US
dc.subjectCaucasianen_US
dc.subjectcomplicationen_US
dc.subjectimmunologyen_US
dc.subjectlungen_US
dc.subjectpathophysiologyen_US
dc.subjectsystemic sclerosisen_US
dc.subjectAdulten_US
dc.subjectAfrican Continental Ancestry Groupen_US
dc.subjectAgeden_US
dc.subjectAsian Continental Ancestry Groupen_US
dc.subjectAutoantibodiesen_US
dc.subjectDNA Topoisomerases, Type Ien_US
dc.subjectEuropean Continental Ancestry Groupen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectHypertension, Pulmonaryen_US
dc.subjectLungen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectScleroderma, Systemicen_US
dc.titleRacial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu